检测非心磷脂负电荷磷脂抗体的免疫测定法的性能评估和临床相关性。
Performance Evaluation and Clinical Associations of Immunoassays That Detect Antibodies to Negatively Charged Phospholipids Other Than Cardiolipin.
机构信息
Rheumatology/Internal Medicine, University of Texas Medical Branch, Galveston.
University of the West Indies, Mona Campus, Kingston, Jamaica.
出版信息
Am J Clin Pathol. 2018 Mar 29;149(5):401-411. doi: 10.1093/ajcp/aqy003.
OBJECTIVES
We evaluate the performance characteristics of antiphosphatidylserine (anti-PS), antiphosphatidylinositol (anti-PI), and antiphospholipid mixture (APhL) enzyme-linked immunosorbent assays (ELISAs) compared with anticardiolipin (aCL) and anti-β2 glycoprotein I (anti-β2GPI) in a large group of patients with antiphospholipid (aPL)-related diseases.
METHODS
Serum samples from 548 patients from the Hopkins and Jamaican systemic lupus erythematosus cohorts, the PROMISSE cohort, and the Antiphospholipid Standardization Laboratory were examined for immunoglobulin G (IgG)/immunoglobulin M (IgM) positivity in aCL, anti-β2GPI, anti-PS, anti-PI, and APhL ELISA assays.
RESULTS
All IgG assays were associated with one or more thrombotic and/or obstetric manifestations, with an increased risk associated with higher antibody titers. Analytical performance was similar among assays, but IgG assays performed better than IgM counterparts.
CONCLUSIONS
Increasing titers of APhL, anti-PS, and anti-PI antibodies could indicate an increased risk of thrombotic and/or obstetric aPL-related manifestations. These assays may be promising biomarkers for particular APS manifestations.
目的
我们评估了抗磷脂酰丝氨酸（anti-PS）、抗磷脂酰肌醇（anti-PI）和抗磷脂混合（APhL）酶联免疫吸附试验（ELISA）与抗心磷脂（aCL）和抗β2 糖蛋白 I（anti-β2GPI）在一大群抗磷脂（aPL）相关疾病患者中的性能特征。
方法
对来自霍普金斯和牙买加系统性红斑狼疮队列、PROMISSE 队列和抗磷脂标准化实验室的 548 名患者的血清样本进行了 IgG/IgM 抗 aCL、抗β2GPI、抗 PS、抗 PI 和 APhL ELISA 检测。
结果
所有 IgG 检测均与一种或多种血栓形成和/或产科表现相关，抗体滴度越高，风险越高。各检测方法的分析性能相似，但 IgG 检测优于 IgM 检测。
结论
APhL、抗 PS 和抗 PI 抗体的滴度升高可能表明血栓形成和/或产科 aPL 相关表现的风险增加。这些检测方法可能是特定 APS 表现的有前途的生物标志物。
Zotero 插件